Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Focus Moves to Copaxone Trial
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $17.00.
Analyst, Ritu Baral, said, "Reiterating rating and price target on generic Copaxone and biosimilars potential, modest enox revenue stream. M-enox revenues are now a modest royalty stream to MNTA. We expect progress on biosimilars candidates from the Baxter deal in 2012/2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."
"We assign an $8/share value to M356, MNTA’s generic version of Teva’s (Nasdaq: TEVA) blockbuster multiple sclerosis drug Copaxone. Hearings in the patent infringement case wrapped up last September, and we expect a decision this summer. We think MNTA is having ongoing talks with FDA on the M356 ANDA."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $14.70 yesterday.
Analyst, Ritu Baral, said, "Reiterating rating and price target on generic Copaxone and biosimilars potential, modest enox revenue stream. M-enox revenues are now a modest royalty stream to MNTA. We expect progress on biosimilars candidates from the Baxter deal in 2012/2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."
"We assign an $8/share value to M356, MNTA’s generic version of Teva’s (Nasdaq: TEVA) blockbuster multiple sclerosis drug Copaxone. Hearings in the patent infringement case wrapped up last September, and we expect a decision this summer. We think MNTA is having ongoing talks with FDA on the M356 ANDA."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $14.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy
- BMO Capital Starts Marvell (MRVL) at Outperform
- Kepler Cheuvreux Downgrades Avantium N.V (AVTX:NA) to Reduce
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
